Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
PALI vs SLN — Stock Comparison
Compare PALI and SLN side-by-side on StoQuant: PALI Q-Score 58 vs SLN 73; analyst signal 73 vs 72. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- PALI — Palisade Bio, Inc. · Health Care · market cap $232M · Q-Score verdict Buy (58.0, grade B) · analyst signal 73/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: analyst consensus 73/100, valuation 50/100 · weakest signals: technicals 25/100, competitive moat 0/100. Full PALI research.
- SLN — Silence Therapeutics plc · Health Care · market cap $929M · Q-Score verdict Strong Buy (73.0, grade A) · analyst signal 72/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 92/100, valuation 74/100 · weakest signals: analyst consensus 62/100, earnings quality 55/100. Full SLN research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: PALI research · SLN research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.